The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma

被引：15
作者：
Kalmadi, Sujith R. [1 ]
Hussein, Mohamad A. [1 ]
机构：
[1] Cleveland Clin Fdn, Multiple Myeloma Multidisciplinary Clin Res Progr, Taussig Canc Ctr, Dept Med Hematol Oncol, Cleveland, OH 44195 USA
来源：
ACTA HAEMATOLOGICA | 2006年 / 116卷 / 01期
关键词：
multiple myeloma; arsenic trioxide; relapsed disease; chemotherapy;
D O I：
10.1159/000092341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Multiple myeloma is a clonal disorder of plasma cells which is considered incurable with currently available therapies. Substantial advances have been achieved in the past decade with the identification of cellular mechanisms that confer drug resistance. This has resulted in newer agents such as arsenic trioxide (Trisenox (TM)), lenalidomide (Revlimid (TM)) and bortezomib (Velcade (TM)) with promising activity in this disease. In this review article we will outline the history, mechanisms of action, pharmacology, and clinical trials of arsenic trioxide in multiple myeloma. Copyright (c) 2006 S. Karger AG, Basel
引用
收藏
页码：1 / 7
页数：7
相关论文
共 45 条
[1]  
Akay C, 2004, CELL CYCLE, V3, P324
[2]   Arsenic Trioxide Selectively Induces Early and Extensive Apoptosis via the APO2/Caspase-8 Pathway Engaging the Mitochondrial Pathway in Myeloma Cells with Mutant p53 [J].
Akay, Cagla ;
Gazitt, Yair .
CELL CYCLE, 2003, 2 (04) :358-368
[3]  
Aronson S M, 1994, R I Med, V77, P233
[4]  
Bahlis NJ, 2002, CLIN CANCER RES, V8, P3658
[5]  
BERENSON EA, 2005, 10 INT MYEL WORKSH S
[6]  
BERENSON EA, 2003, INT WORKSH MULT MYEL
[7]  
BIRCH R, 2003, AM SOC HEM 45 ANN M
[8]  
BORAD M, 2003, AM SOC HEM 45 ANN M
[9]   Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide [J].
Camacho, LH ;
Soignet, SL ;
Chanel, S ;
Ho, R ;
Heller, G ;
Scheinberg, DA ;
Ellison, R ;
Warrell, RP .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (13) :2620-2625
[10]  
CHANANKHAN AA, 2003, AM SOC HEM 45 ANN M
12345